Exagen Inc.
A medical diagnostics company, Exagen makes blood tests that help rheumatologists tell apart autoimmune conditions like lupus and rheumatoid arthritis. Its flagship product, AVISE CTD, is processed in a single lab in Vista, California, with results typically ready in about five business days. Founded in 2002, the company grows its line of AVISE-branded tests, and the "CTD" in its flagship test's name stands for connective tissue disease—the family of illnesses it helps doctors sort out.
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
Exagen's operating loss narrowed to its smallest on record. rose 15.9% to $19.9 million, expanded to 61.3%, and the operating loss shrank to $1.7 million as higher testing volume and pricing flowed through. The company is approaching breakeven, but cash reserves remain thin at $24.6 million.
Exagen states it is not currently party to any material legal proceedings.
There have been no material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" of our 2025 Annual Report. 36
There have been no material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" of our 2025 Annual Report. 36
Read original filing text →